Home LiteratureArticle Details
PMID: 8011834 Published · ppublish English Case Reports Journal Article Review

Necrotizing pneumonia caused by mixed infection with Actinobacillus actinomycetemcomitans and Actinomyces israelii: case report and review.

Morris JF, Sewell DL

Abstract

Actinobacillus actinomycetemcomitans is an important cause of human pulmonary infections, either alone or with Actinomyces species. It may be critical to isolate Actinobacillus in patients with pulmonary infection for selection of an effective antimicrobial regimen. Clindamycin has superseded penicillin as the sole antimicrobial drug for anaerobic bacterial necrotizing pneumonia and abscess. In the case presented herein, therapy with clindamycin failed to halt worsening necrotizing pneumonia or to prevent hematogenous dissemination. After clindamycin-resistant A. actinomycetemcomitans in addition to Actinomyces israelii were isolated, the patient was treated with penicillin, ciprofloxacin, and cefazolin and was ultimately cured.

MeSH Terms
Actinobacillus Infections/complications Actinomycosis/complications Aggregatibacter actinomycetemcomitans/drug effects Clindamycin/therapeutic use Drug Resistance, Microbial Drug Therapy, Combination/therapeutic use Humans Male Middle Aged Necrosis Pneumonia/complications,pathology
Chemicals
Clindamycin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Morris J F
Medical Service, Veterans Affairs Medical Center, Portland, Oregon 97207.
Sewell D L
Article Info
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Abbr.
Clin Infect Dis
ISSN
1058-4838
Published
1994-03-00
Pages
450-2
Language
English
Region
United States
NLM ID
9203213
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com